School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
J Photochem Photobiol B. 2010 Oct 5;101(1):59-69. doi: 10.1016/j.jphotobiol.2010.06.012. Epub 2010 Jun 30.
In photodynamic therapy (PDT) a combination of visible light and a sensitising drug causes the destruction of selected cells. Aminolaevulinic acid (ALA) has been widely used in topical PDT for over 15 years. However, ALA does not possess favourable physicochemical properties for skin penetration. Consequently, the clearance rates for difficult to treat lesions, such as nodular basal cell carcinomas are relatively low. For the first time, equimolar concentrations of ALA, methyl-ALA (m-ALA) and hexyl-ALA (h-ALA) have been incorporated into a bioadhesive patch-based system. In vitro penetration studies into excised porcine skin revealed that ALA patches containing relatively high loadings (226.7 micromol cm(-2)) were associated with significantly greater tissue concentrations (70.7 micromol cm(-3)) than patches containing m-ALA (16.3 micromol cm(-3)) or h-ALA (17.4 micromol cm(-3)). ALA was also found to be the most efficient inducer of protoporphyrin (PpIX) fluorescence in mice, in vivo (maximum mean fluorescence: ALA=236.2 a.u., m-ALA=175.1 a.u., h-ALA=193.5 a.u.). However, when the lipophilic hexylester was formulated in a pressure sensitive adhesive (PSA) patch, significantly higher PpIX levels were achieved compared to all bioadhesive systems tested. Of major importance, PSA patches containing relatively low h-ALA loadings induced high PpIX levels, which were localised to the application area. This study has highlighted the importance of rational selection of both the active agent and the delivery system. Bioadhesive preparations containing ALA are ideal for delivery to moist environments; whereas h-ALA-loaded PSA systems may facilitate enhanced delivery to dry areas of skin. In addition, owing to the relatively low loadings of h-ALA required in PSA patches, the costs of clinical PDT may potentially be reduced.
在光动力疗法(PDT)中,可见光和敏化药物的组合会导致选定细胞的破坏。氨基酮戊酸(ALA)已广泛用于局部 PDT 超过 15 年。然而,ALA 没有适合皮肤穿透的物理化学性质。因此,对于难以治疗的病变,例如结节性基底细胞癌,清除率相对较低。首次将等摩尔浓度的 ALA、甲基-ALA(m-ALA)和己基-ALA(h-ALA)纳入基于生物粘附贴剂的系统中。体外渗透研究表明,含有相对高载药量(226.7µmol/cm²)的 ALA 贴片与含有 m-ALA(16.3µmol/cm³)或 h-ALA(17.4µmol/cm³)的贴片相比,与组织浓度(70.7µmol/cm³)显著更高。还发现 ALA 是体内(最大平均荧光:ALA=236.2a.u.,m-ALA=175.1a.u.,h-ALA=193.5a.u.)诱导原卟啉(PpIX)荧光最有效的诱导剂。然而,当疏水性己酯在压敏性粘合剂(PSA)贴剂中形成时,与所有测试的生物粘附系统相比,实现了更高的 PpIX 水平。重要的是,含有相对低 h-ALA 载药量的 PSA 贴片诱导了高 PpIX 水平,这些水平定位于应用区域。这项研究强调了合理选择活性剂和输送系统的重要性。含有 ALA 的生物粘附制剂是用于输送到潮湿环境的理想选择;而 h-ALA 负载的 PSA 系统可能有助于增强对干燥皮肤区域的输送。此外,由于 PSA 贴片中所需的 h-ALA 相对较低的载药量,临床 PDT 的成本可能会降低。